Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1994 3
1995 1
1996 5
1997 12
1998 42
1999 61
2000 71
2001 102
2002 94
2003 100
2004 102
2005 87
2006 79
2007 51
2008 68
2009 66
2010 74
2011 69
2012 68
2013 59
2014 51
2015 62
2016 67
2017 54
2018 61
2019 62
2020 81
2021 91
2022 80
2023 94
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

1,784 results

Results by year

Filters applied: . Clear all
Page 1
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
Zi W, Song J, Kong W, Huang J, Guo C, He W, Yu Y, Zhang B, Geng W, Tan X, Tian Y, Liu Z, Cao M, Cheng D, Li B, Huang W, Liu J, Wang P, Yu Z, Liang H, Yang S, Tang M, Liu W, Huang X, Liu S, Tang Y, Wu Y, Yao L, Shi Z, He P, Zhao H, Chen Z, Luo J, Wan Y, Shi Q, Wang M, Yang D, Chen X, Huang F, Mu J, Li H, Li Z, Zheng J, Xie S, Cai T, Peng Y, Xie W, Qiu Z, Liu C, Yue C, Li L, Tian Y, Yang D, Miao J, Yang J, Hu J, Nogueira RG, Wang D, Saver JL, Li F, Yang Q; RESCUE BT2 Investigators. Zi W, et al. N Engl J Med. 2023 Jun 1;388(22):2025-2036. doi: 10.1056/NEJMoa2214299. N Engl J Med. 2023. PMID: 37256974 Clinical Trial.
BACKGROUND: The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied. ...The incidence of symptomatic intra …
BACKGROUND: The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have …
Tirofiban-induced thrombocytopenia.
Wang J, Zou D. Wang J, et al. Ann Med. 2023 Dec;55(1):2233425. doi: 10.1080/07853890.2023.2233425. Ann Med. 2023. PMID: 37439782 Free PMC article. Review.
Tirofiban is a small non-peptide ligand-mimetic Glycoprotein (GP) IIb/IIIa inhibitor which can reversibly bind to the arginine-glycine-aspartic acid (RGD) recognition site of GP IIb/IIIa to prevent platelet aggregation. ...The present review provides an overview of the pat
Tirofiban is a small non-peptide ligand-mimetic Glycoprotein (GP) IIb/IIIa inhibitor which can reversibly bind to the arginine-glycin
Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.
RESCUE BT Trial Investigators; Qiu Z, Li F, Sang H, Luo W, Liu S, Liu W, Guo Z, Li H, Sun D, Huang W, Zhang M, Zhang M, Dai W, Zhou P, Deng W, Zhou Z, Huang X, Lei B, Li J, Yuan Z, Song B, Miao J, Liu S, Jin Z, Zeng G, Zeng H, Yuan J, Wen C, Yu Y, Yuan G, Wu J, Long C, Luo J, Tian Z, Zheng C, Hu Z, Wang S, Wang T, Qi L, Li R, Wan Y, Ke Y, Wu Y, Zhu X, Kong W, Huang J, Peng D, Chang M, Ge H, Shi Z, Yan Z, Du J, Jin Y, Ju D, Huang C, Hong Y, Liu T, Zhao W, Wang J, Zheng B, Wang L, Liu S, Luo X, Luo S, Xu X, Hu J, Pu J, Chen S, Sun Y, Jiang S, Wei L, Fu X, Bai Y, Yang S, Hu W, Zhang G, Pan C, Zhang S, Wang Y, Cao W, Yang S, Zhang J, Guo F, Wen H, Zhang J, Song J, Yue C, Li L, Wu D, Tian Y, Yang J, Lu M, Saver JL, Nogueira RG, Zi W, Yang Q. RESCUE BT Trial Investigators, et al. JAMA. 2022 Aug 9;328(6):543-553. doi: 10.1001/jama.2022.12584. JAMA. 2022. PMID: 35943471 Free PMC article. Clinical Trial.
The median (IQR) 90-day modified Rankin Scale score in the tirofiban group vs placebo group was 3 (1-4) vs 3 (1-4). The adjusted common odds ratio for a lower level of disability with tirofiban vs placebo was 1.08 (95% CI, 0.86-1.36). ...The findings do not support …
The median (IQR) 90-day modified Rankin Scale score in the tirofiban group vs placebo group was 3 (1-4) vs 3 (1-4). The adjusted comm …
Tirofiban in emergency conditions.
Szarpak L, Rafique Z, Gasecka A, Jaguszewski MJ, Filipiak KJ. Szarpak L, et al. Am J Emerg Med. 2022 Jan;51:422-423. doi: 10.1016/j.ajem.2021.03.063. Epub 2021 Mar 24. Am J Emerg Med. 2022. PMID: 33824023 Review. No abstract available.
Association of Tirofiban With Functional Outcomes After Thrombectomy in Acute Ischemic Stroke Due to Intracranial Atherosclerotic Disease.
Sang H, Xie D, Tian Y, Nguyen TN, Saver JL, Nogueira RG, Wu J, Long C, Tian Z, Hu Z, Wang T, Li R, Ke Y, Zhu X, Peng D, Chang M, Li L, Ruan J, Wu D, Zi W, Yang Q, Li F, Qiu Z. Sang H, et al. Neurology. 2023 May 9;100(19):e1996-e2006. doi: 10.1212/WNL.0000000000207194. Epub 2023 Mar 20. Neurology. 2023. PMID: 36941074 Clinical Trial.
Tirofiban was associated with fewer thrombectomy passes (median [IQR] 1 [1-2] vs 1 [1-2], p = 0.004), which was an independent predictor of functional independence. Mediation analysis showed tirofiban-reduced thrombectomy passes explained 20.0% (95% CI 4.1%-76.0%) o
Tirofiban was associated with fewer thrombectomy passes (median [IQR] 1 [1-2] vs 1 [1-2], p = 0.004), which was an independent predic
Intravenous tirofiban therapy for patients with capsular warning syndrome.
Li W, Wu Y, Li XS, Liu CC, Huang SH, Liang CR, Wang H, Zhang LL, Xu ZQ, Wang YJ, Zhang M. Li W, et al. Stroke Vasc Neurol. 2019 Jan 9;4(1):22-27. doi: 10.1136/svn-2018-000163. eCollection 2019 Mar. Stroke Vasc Neurol. 2019. PMID: 31105975 Free PMC article. Review.
There is no effective therapy to stop these attacks. We, herein, report our experience of using intravenous tirofiban to treat CWS. METHODS: All patients with CWS in our hospital from January 2013 to September 2017 were reviewed. Patients in tirofiban group (T-group …
There is no effective therapy to stop these attacks. We, herein, report our experience of using intravenous tirofiban to treat CWS. M …
Tirofiban-Induced Severe Thrombocytopenia.
Liu YY, Dong QT, Guo YL, Wu NQ, Li JJ. Liu YY, et al. Am J Ther. 2019 Sep/Oct;26(5):e659-e661. doi: 10.1097/MJT.0000000000000861. Am J Ther. 2019. PMID: 31356349 No abstract available.
The Application of Tirofiban in the Endovascular Treatment of Acute Ischemic Stroke: A Meta-Analysis.
Tang L, Tang X, Yang Q. Tang L, et al. Cerebrovasc Dis. 2021;50(2):121-131. doi: 10.1159/000512601. Epub 2021 Jan 5. Cerebrovasc Dis. 2021. PMID: 33401276 Free article. Review.
There were no statistically significant differences in the incidence of symptomatic intracranial hemorrhage (OR = 0.97, 95% CI [0.73, 1.31], p = 0.86) and intracranial hemorrhage (OR = 1.08, 95% CI [0.59, 1.97], p = 0.80) between tirofiban and non-tirofiban group. B …
There were no statistically significant differences in the incidence of symptomatic intracranial hemorrhage (OR = 0.97, 95% CI [0.73, 1.31], …
Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke.
Yang M, Huo X, Miao Z, Wang Y. Yang M, et al. Drugs. 2019 Apr;79(5):515-529. doi: 10.1007/s40265-019-01078-0. Drugs. 2019. PMID: 30838514 Review.
The adjunctive use of tirofiban has been extensively evaluated in progressive stroke, combined intravenous thrombolysis (IVT), and endovascular treatment (EVT) in both preclinical and clinical studies. ...Substantial practical progress is likely as our understanding of the …
The adjunctive use of tirofiban has been extensively evaluated in progressive stroke, combined intravenous thrombolysis (IVT), and en …
Safety and efficacy of tirofiban in the management of stroke: A systematic review and meta-analysis of randomized controlled trials.
Al-Salihi MM, Ayyad A, Al-Jebur MS, Al-Salihi Y, Saha R, Morsi RZ, Kass-Hout T, Kasab SA, Spiotta AM. Al-Salihi MM, et al. Clin Neurol Neurosurg. 2023 Sep;232:107867. doi: 10.1016/j.clineuro.2023.107867. Epub 2023 Jun 29. Clin Neurol Neurosurg. 2023. PMID: 37423089 Free article. Review.
RESULTS: Seven RCTs with 2088 stroke patients were included. Tirofiban significantly increased the number of patients with mRS 0 score after 90 days than control; RR= 1.39, 95 %CI [1.15, 1.69]; p = 0.0006. ...Other assessed outcomes showed insignificant results. CONCLUSION …
RESULTS: Seven RCTs with 2088 stroke patients were included. Tirofiban significantly increased the number of patients with mRS 0 scor …
1,784 results